Speculators who bought into a risky three-drug bet are still on track for a payout following Celgene's merger with Bristol-Myers Squibb, after the FDA agreed to fast-track its review of a n
NICE said “no” to NHS funding for a combination of MSD’s Keytruda (pembrolizumab) immunotherapy and Pfizer’s Inlyta (axitinib) in untreated kidney cancer, citing uncertainties about its lon
